Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

carbon C 14 mivavotinib citrate

A radioconjugate composed of the citrate form of mivavotinib, an orally bioavailable selective inhibitor of the non-receptor tyrosine kinase (RTK) spleen tyrosine kinase (Syk), labeled with the radioisotope carbon C 14, with potential use for evaluating the pharmacokinetic profile of mivavotinin. Upon administration of carbon C 14 mivavotinib citrate, mivavotinib targets, binds to and inhibits Syk. Labeling of mivavotinib with the radioactive tracer carbon C 14 permits the evaluation of this agent's pharmacokinetic profile, including its absorption, distribution, metabolism, and excretion (ADME). Syk, a B-cell receptor (BCR)-associated non-receptor tyrosine kinase that mediates B-cell activation, chemotaxis, adhesion and proliferation, is expressed in hematopoietic tissues and is often overexpressed in hematopoietic malignancies.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:[14 C]-TAK-659
[14C]TAK 659
[14C]TAK-659
14C-labeled mivavotinib citrate
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search